Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium ulcer approval

This article was originally published in The Tan Sheet

Executive Summary

AstraZeneca receives EU approval to market prescription proton pump inhibitor Nexium for the treatment of gastric ulcers and prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory (NSAID) therapy, firm announces Sept. 16. Research into the treatment of NSAID-associated upper GI side effects demonstrated that Nexium "can effectively heal gastric ulcers and prevent gastric and duodenal ulcers associated with long-term NSAID use, as well as relieve other painful upper GI symptoms such as epigastric pain, heartburn and acid reflux," according to Nexium NSAID program lead investigator Chris Hawkey, University Hospital, Nottingham, England. AstraZeneca applied for the same indications for Nexium in the U.S. earlier this year...

You may also be interested in...



Waylivra Funding Success In England & Germany

Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.

Fresenius Faces French Damages Over Alimta

Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel